Only 12 injections a year? New obesity drug could change weight loss treatment
Pfizer's berobenatide, a monthly GLP-1 therapy, has shown positive results in mid-stage trials for weight loss and diabetes management. It could potentially revolutionize obesity treatment by reducing the need for weekly injections. However, experts urge caution in comparing it to other drugs and stress the need for long-term safety and efficacy data.